CytoDyn, Inc. (CYDY)
0.20
0.00 (0.00%)
USD |
OTCM |
Oct 14, 16:00
CytoDyn EPS Diluted (Quarterly) : -0.0147 for Aug. 31, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| August 31, 2026 | -0.0147 |
| May 31, 2026 | -0.0074 |
| February 28, 2026 | -0.004 |
| November 30, 2025 | -0.0182 |
| August 31, 2025 | -0.0047 |
| May 31, 2025 | -0.0051 |
| February 28, 2025 | -0.0042 |
| November 30, 2024 | -0.0042 |
| August 31, 2024 | 0.0157 |
| May 31, 2024 | -0.0172 |
| February 29, 2024 | -0.0125 |
| November 30, 2023 | -0.0104 |
| August 31, 2023 | -0.0129 |
| May 31, 2023 | -0.0207 |
| February 28, 2023 | -0.017 |
| November 30, 2022 | -0.0344 |
| August 31, 2022 | -0.0324 |
| May 31, 2022 | -0.1535 |
| February 28, 2022 | -0.0599 |
| November 30, 2021 | -0.0611 |
| August 31, 2021 | -0.0723 |
| May 31, 2021 | -0.1039 |
| February 28, 2021 | -0.0782 |
| November 30, 2020 | -0.0613 |
| August 31, 2020 | -0.0555 |
| Date | Value |
|---|---|
| May 31, 2020 | -0.111 |
| February 29, 2020 | -0.0828 |
| November 30, 2019 | -0.0382 |
| August 31, 2019 | -0.0443 |
| May 31, 2019 | -0.0462 |
| February 28, 2019 | -0.0425 |
| November 30, 2018 | -0.0552 |
| August 31, 2018 | -0.07 |
| May 31, 2018 | -0.04 |
| February 28, 2018 | -0.10 |
| November 30, 2017 | -0.07 |
| August 31, 2017 | -0.08 |
| May 31, 2017 | -0.0457 |
| February 28, 2017 | -0.06 |
| November 30, 2016 | -0.04 |
| August 31, 2016 | -0.04 |
| May 31, 2016 | -0.05 |
| February 29, 2016 | -0.05 |
| November 30, 2015 | -0.06 |
| August 31, 2015 | -0.12 |
| May 31, 2015 | -0.22 |
| February 28, 2015 | -0.05 |
| November 30, 2014 | -0.09 |
| August 31, 2014 | -0.06 |
| May 31, 2014 | -0.0537 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.94M |
| Total Expenses (Quarterly) | 19.94M |
| Enterprise Value | 301.78M |
| Earnings Yield | -22.15% |
| Normalized Earnings Yield | -14.15 |